000124051 001__ 124051
000124051 005__ 20241125101130.0
000124051 0247_ $$2doi$$a10.1080/2162402X.2022.2160094
000124051 0248_ $$2sideral$$a132593
000124051 037__ $$aART-2023-132593
000124051 041__ $$aeng
000124051 100__ $$aEsteso, Gloria
000124051 245__ $$aBCG-activation of leukocytes is sufficient for the generation of donor-independent innate anti-tumor NK and ¿d T-cells that can be further expanded <i>in vitro</i>
000124051 260__ $$c2023
000124051 5060_ $$aAccess copy available to the general public$$fUnrestricted
000124051 5203_ $$aBacillus Calmette-Guérin (BCG), the nonpathogenic Mycobacterium bovis strain used as tuberculosis vaccine, has been successfully used as treatment for non-muscle invasive bladder cancer for decades, and suggested to potentiate cellular and humoral immune responses. However, the exact mechanism of action is not fully understood. We previously described that BCG mainly activated anti-tumor cytotoxic NK cells with upregulation of CD56 and a CD16+ phenotype. Now, we show that stimulation of human peripheral blood mononuclear cells with iBCG, a preparation based on BCG-Moreau, expands oligoclonal γδ T-cells, with a cytotoxic phenotype, together with anti-tumor CD56high CD16+ NK cells. We have used scRNA-seq, flow cytometry, and functional assays to characterize these BCG-activated γδ T-cells in detail. They had a high IFNγ secretion signature with expression of CD27+ and formed conjugates with bladder cancer cells. BCG-activated γδ T-cells proliferated strongly in response to minimal doses of cytokines and had anti-tumor functions, although not fully based on degranulation. BCG was sufficient to stimulate proliferation of γδ T-cells when cultured with other PBMC; however, BCG alone did not stimulate expansion of purified γδ T-cells. The characterization of these non-donor restricted lymphocyte populations, which can be expanded in vitro, could provide a new approach to prepare cell-based immunotherapy tools.
000124051 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc$$uhttp://creativecommons.org/licenses/by-nc/3.0/es/
000124051 590__ $$a6.5$$b2023
000124051 592__ $$a2.345$$b2023
000124051 591__ $$aONCOLOGY$$b45 / 322 = 0.14$$c2023$$dQ1$$eT1
000124051 593__ $$aImmunology$$c2023$$dQ1
000124051 591__ $$aIMMUNOLOGY$$b31 / 181 = 0.171$$c2023$$dQ1$$eT1
000124051 593__ $$aOncology$$c2023$$dQ1
000124051 593__ $$aImmunology and Allergy$$c2023$$dQ1
000124051 594__ $$a12.8$$b2023
000124051 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000124051 700__ $$aFelgueres, María José
000124051 700__ $$aGarcía Jiménez, Álvaro F.
000124051 700__ $$aReyburn Valés, Christina
000124051 700__ $$aBenguría, Alberto
000124051 700__ $$aVázquez, Enrique
000124051 700__ $$aReyburn, Hugh T.
000124051 700__ $$0(orcid)0000-0001-7897-9173$$aAguiló, Nacho$$uUniversidad de Zaragoza
000124051 700__ $$0(orcid)0000-0003-2993-5478$$aMartín, Carlos$$uUniversidad de Zaragoza
000124051 700__ $$aPuentes, Eugenia
000124051 700__ $$aMurillo, Ingrid
000124051 700__ $$aRodríguez, Esteban
000124051 700__ $$aValés-Gómez, Mar
000124051 7102_ $$11011$$2630$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Microbiología
000124051 7102_ $$11011$$2566$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Inmunología
000124051 773__ $$g12, 1 (2023), 2160094 [16 pp]$$pOncoimmunology$$tOncoImmunology$$x2162-4011
000124051 8564_ $$s5719225$$uhttps://zaguan.unizar.es/record/124051/files/texto_completo.pdf$$yVersión publicada
000124051 8564_ $$s1402103$$uhttps://zaguan.unizar.es/record/124051/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000124051 909CO $$ooai:zaguan.unizar.es:124051$$particulos$$pdriver
000124051 951__ $$a2024-11-22-11:58:47
000124051 980__ $$aARTICLE